These posters, oral presentations, and/or abstracts are provided for medical and scientific purposes only, they may include investigational use or agents that are not approved by health authorities. The information presented is not meant to convey conclusions of safety or effectiveness prior to any regulatory approval from a health authority.
Sanofi does not recommend the use of any products in a manner inconsistent with that described in the full prescribing information. Please refer to the prescribing information in your country of practice for any medicinal products mentioned.
Availability of posters and/or abstracts on this site will conform with conference embargo policies. By selecting “Accept”, you are certifying that you are a Healthcare Professional.
ASCO 2026 | May 29, 2026 - Jun 2, 2026
Multiple myeloma (MM) is a malignancy of antibody-secreting plasma cells and is the second most common hematologic malignancy worldwide, representing a significant cause of cancer-related mortality. MM remains an incurable disease with many patients relapsing multiple times throughout the course of the treatment.
